Skip to main content

Arbli Dosage

Generic name: LOSARTAN POTASSIUM 10mg in 1mL
Dosage form: oral suspension
Drug class: Angiotensin receptor blockers

Medically reviewed by Drugs.com. Last updated on Mar 20, 2025.

Important Administration Information

Instruct patients or caregivers to use oral dosing syringe(s) or an oral dosing cup to measure the prescribed amount of medication. Inform patients that oral dosing syringe(s) or an oral dosing cup may be obtained from their pharmacy.

2.2 Hypertension

Adult Hypertension

The usual starting dose of Arbli is 50 mg orally once daily. The dosage can be increased to a maximum dose of 100 mg orally once daily as needed to control blood pressure. A starting dose of 25 mg once daily is recommended for patients with possible intravascular depletion (e.g., on diuretic therapy).

Pediatric Hypertension

The usual recommended starting dose is 0.7 mg per kg orally once daily (up to 50 mg total) administered as a suspension. Dosage should be adjusted according to blood pressure response. Doses above 1.4 mg per kg (or in excess of 100 mg) daily have not been studied in pediatric patients.

Arbli is not recommended in pediatric patients less than 2 years of age or in pediatric patients with estimated glomerular filtration rate less than 30 mL/min/1.73 m2 .

2.3 Hypertensive Patients with Left Ventricular Hypertrophy

The usual starting dose is 50 mg of Arbli orally once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of Arbli should be increased to 100 mg orally once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response.

2.4 Nephropathy in Type 2 Diabetic Patients

The usual starting dose is 50 mg orally once daily. The dose should be increased to 100 mg orally once daily based on blood pressure response.

2.5 Dosage Modifications in Patients with Hepatic Impairment

In patients with mild-to-moderate hepatic impairment the recommended starting dose of Arbli is 25 mg orally once daily. Arbli has not been studied in patients with severe hepatic impairment.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.